Algorae Pharmaceuticals Limited
LVCLF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.28 | 0.00 | 0.11 | -0.04 |
| FCF Yield | -0.00% | -0.02% | -3.13% | -5.59% |
| EV / EBITDA | 0.00 | 0.00 | -30.98 | -30.34 |
| Quality | ||||
| ROIC | -75.54% | -26.59% | -20.80% | -40.08% |
| Gross Margin | 0.00% | 0.00% | 100.00% | 0.00% |
| Cash Conversion Ratio | 0.56 | 1.07 | 0.80 | 695.10 |
| Growth | ||||
| Revenue 3-Year CAGR | -25.06% | -40.52% | -40.73% | -70.94% |
| Free Cash Flow Growth | 87.90% | 99.86% | 48.97% | -20.96% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | 7.22 | 1.08 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 20.83 | 0.00 |